CDH1 and cancer: In addition, examinations of E-cadherin and N-cadherin, additional cancer metastasis biomarkers that are known to act as a switch in epithelial-mesenchymal transition [20], revealed the up-regulation of E-cadherin but the down-regulation of N-cadherin following HCA treatment, further supporting the antimetasitatic effects of HCA (Figure 3).